PeerView Internal Medicine CME/CNE/CPE Audio Podcast Juan Fortea, MD, PhD / Professor Frank Jessen, MD - Strategies for Appropriate Assessment and Use of APOE Status in Alzheimer’s Disease: Clinical Care in Europe
Mar 12, 2026
Frank Jessen, MD, a professor of psychiatry and dementia specialist from the University Hospital of Cologne, guides practical APOE testing in Europe. He discusses APOE allele effects, geographic and age-related risk patterns, ARIA risk with anti-amyloid therapies, regulatory impacts on treatment eligibility, and step-by-step workflows for counseling, testing, and post-test follow-up.
AI Snips
Chapters
Transcript
Episode notes
APOE4 Greatly Raises AD Risk And Hastens Onset
- APOE genotype strongly alters Alzheimer's disease risk and age at symptom onset.
- APOE4 heterozygotes have ~3–4× risk and present 2–5 years earlier; homozygotes have up to ~15× risk and ~10 years earlier onset.
APOE4 Drives Amyloid Deposition And Vascular Amyloid
- APOE4 promotes amyloid accumulation and reduces amyloid clearance, increasing both parenchymal amyloid and cerebral amyloid angiopathy.
- This dual effect explains enrichment of APOE4 in AD dementia and higher rates of vascular amyloid comorbidity.
APOE Risk Is Age Dependent And Stronger For Biomarkers
- APOE-related risk varies by age and is larger when assessing biomarker (amyloid) positivity than clinical dementia alone.
- APOE4 carriers show earlier biomarker positivity and clinical onset, so age modulates APOE odds ratios.